AI matches the accuracy of expert radiologists to detect prostate cancer in a major multi-centre clinical study
Lucida Medical and Hampshire Hospitals NHS Foundation Trust announce the results of a 5-year collaboration. The PAIR-1 study shows that the Pi AI software, now in use in NHS and European hospitals, is the first commercial product of its kind with performance equivalent to that of expert radiologists to detect prostate cancer, the most common cancer in men.
Appointment of new Vice President of Sales and Marketing at Lucida Medical
We are pleased to announce the appointment of Corina Cucuruzac as Vice President of Sales and Marketing at Lucida Medical, effective immediately.
Lucida Medical Ltd announces a distribution agreement with Sectra to offer Pi AI technology to help diagnose prostate cancer
Lucida Medical announces that it has signed a distribution agreement with international medical imaging IT and cybersecurity company Sectra.
Somerset’s NHS pioneers clinical use of AI software to transform prostate cancer diagnosis
A ground breaking way of supporting doctors to diagnose prostate cancer using the latest artificial intelligence (AI) technology has launched in Somerset.
Lucida Medical and Hampshire Hospitals NHS Foundation Trust announce major study on AI for prostate cancer
Lucida Medical Ltd, the Cambridge-based start-up, and Hampshire Hospitals NHS Foundation Trust (HHFT), have initiated a ground-breaking, collaborative multi-centre research project. This is the first retrospective study in the UK to validate the use of AI to help identify prostate cancer using real-world data from a range of hospitals and scanner types. It will demonstrate the potential of this…